Updates are available Correction dated 2023-12-15

Article History

Received: 21 March 2023

Accepted: 30 June 2023

First Online: 4 August 2023

Change Date: 13 December 2023

Change Type: Update

Change Details: This article has been corrected since original publication; please see the linked erratum for further details.

Change Date: 15 December 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13071-023-06061-z

Declarations

:

: The study protocol was approved by the Institutional Ethics Committee of the Faculty of Medicine and Dentistry of Bamako under the reference number no. 2018/71/CE/FMPOS. School authorities, teachers, parents/guardians and children were informed about the objectives, procedures and potential risks and benefits of the study. Written informed consent was obtained from children’s parents or legal guardians, while children provided oral assent. After sampling, a praziquantel treatment following WHO guidelines (40 mg/kg) was provided to children found to have a <i>Schistosoma</i> infection. For data protection purposes, an identification number was assigned to each participant.

: The Directors of Fangouné Bamanan and Diakalel School obtained informed consent from the parents of all the schoolchildren who participated to the study. Data set availability: Sequence data will be deposited in the NCBI GenBank database Cox 1 DNA.

: Not applicable.

: The authors declare that they have no conflict of interest. Ethical approval Ethical permission was obtained from the Ethics Committee of the Faculté de Médecin et d’Odontostomatologie FMOS de Bamako, Mali. T.S. is an employee of Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany.